Newt talks with Jonathan Dickinson, CEO and José Inzunza, Chief Medical Officer, Co-Founders of Ambio Life Sciences, a global leader in integrative Ibogaine treatment. They discuss the potential of Ibogaine as a therapy for post-traumatic stress disorder, opioid addiction, and depression. Ibogaine is classified as a Schedule I controlled substance by the U.S. Drug Enforcement Agency and is primarily administered in treatment facilities outside the U.S., such as in Mexico and Canada. They talk about their experiences administering Ibogaine and insights into its therapeutic effects, particularly the ability to mitigate opioid withdrawal symptoms and improve neurological health. They also highlight the importance of patient preparation and the need for ongoing support post-treatment to prevent relapse. Ambio Life Sciences collaborated with Stanford University and their pioneering clinical program for neurodegenerative diseases to study conditions like Parkinson's and multiple sclerosis. Their discussion underscores Ibogaine's potential to revolutionize addiction treatment and neurological health.

<p>Newt talks with Jonathan Dickinson, CEO and Jos&eacute; Inzunza, Chief Medical Officer, Co-Founders of Ambio Life Sciences, a global leader in integrative Ibogaine treatment. They discuss the potential of Ibogaine as a therapy for post-traumatic stress disorder, opioid addiction, and depression. Ibogaine is classified as a Schedule I controlled substance by the U.S. Drug Enforcement Agency and is primarily administered in treatment facilities outside the U.S., such as in Mexico and Canada. They talk about their experiences administering Ibogaine and insights into its therapeutic effects, particularly the ability to mitigate opioid withdrawal symptoms and improve neurological health. They also highlight the importance of patient preparation and the need for ongoing support post-treatment to prevent relapse. Ambio Life Sciences collaborated with Stanford University and their pioneering clinical program for neurodegenerative diseases to study conditions like Parkinson's and multiple sclerosis. Their discussion underscores Ibogaine's potential to revolutionize addiction treatment and neurological health.</p>

Join former House Speaker, professor, historian, and futurist Newt Gingrich as he shares his lifetime of knowledge and access to the world’s most interesting minds in a new series that covers all aspects of our society. From history to health, national security to science, Newt offers stories, conversations, and context to uncover new perspectives, knowledge and insight. This podcast isn’t about politics; it’s about exploring the past, present, and future to understand where we’ve been and where we’re going. Welcome to Newt’s World, a podcast for independent thinkers.

Newt's World

Episode 872: Ibogaine – Inside a Treatment Facility

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d05c6b9a-3da1-4a98-be92-b31e01856fd7/transcript

Advertisement